Displaying 1 - 1 of 1
| Active Ingredient | DAPAGLIFLOZIN | METFORMIN |
| Therapeutic Class | SODIUM-GLUCOSE COTRANSPORTER INHIBITOR |
| Indications | As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both dapagliflozin and metformin is appropriate. |
| Caution | Back pain; balanoposthitis; dizziness; dyslipidaemia; hypoglycaemia (in combination with insulin or sulphonylurea); increased risk of genital mycotic infection in both males and females; rash; increas More ... |
| Dose Range | The usual oral dose is 5 or 10 mg once daily. Doses of insulin, sulfonylurea, and other insulin secretagogues may need to be lowered when used with dapagliflozin. The dose of dapagliflozin should be reduced in hepatic impairment. |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |